Søk. Nøkkelinformasjon. Sammendrag og figur. Klasser. IPC-klasse. Søker. Innehaver. Finn patenter, varemerker og design i Norge

Transkript

1 Søk Finn patenter, varemerker og design i Norge Nøkkelinformasjon Databasen er sist oppdatert :14:00 Tittel Status Hovedstatus Detaljstatus Patentnummer Europeisk (EP) publiserings nummer K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY I kraft EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge NO/EP EP EP inngitt EP søknadsnummer EP meddelt Prioritet Sakstype , P Europeisk Løpedag Utløpsdato Allment tilgjengelig Validert i Norge Innehaver Oppfinner Fullmektig Lenke til European patent Register Patentfamilie Amgen Inc. () FREEMAN, Daniel () Onsagers AS (NO) Informasjon i saken, dokumenter og patentfamilie Se i Espacenet Sammendrag og figur Se forsidefigur og sammendrag i Espacenet Klasser IPC-klasse C12Q 1/68 G01N 33/574 Søker Innehaver Innehaver i EP:

2 Amgen Inc. One Amgen Center Drive Thousand Oaks, CA Oppfinner FREEMAN, Daniel 942 Grayrock Street Newbury Park, CA JUAN, Todd 4629 Calle San Juan Newbury Park, CA RADINSKY, Robert 3574 Lang Ranch Parkway Thousand Oaks, CA Fullmektig Fullmektig i Norge: Onsagers AS Se mer Postboks 1813 Vika 0123 OSLO NO ( OSLO kommune, OSLO fylke ) Org.nummer: Referanse på sak: P23749NOEP Fullmektig i EP: Grünecker Patent- und Rechtsanwälte PartG mbb Leopoldstraße München DE Prioritet , P Anførte dokumenter WO-A-2007/ (B1/EP) EBERHARD D A ET AL: "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib" JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 23, no. 25, 1 September 2004 ( ), pages , XP ISSN: X (B1/EP) PAO W ET AL: "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib" PLOS MEDICINE 2005, vol. 2, no. 1, 2005, pages , XP ISSN: (B1/EP) LIÈVRE ASTRID ET AL: "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer." CANCER RESEARCH 15 APR 2006, vol. 66, no. 8, 15 April 2006 ( ), pages , XP ISSN: (B1/EP) BENVENUTI SILVIA ET AL: "Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies" , 15 March 2007 ( ), XP (B1/EP)

3 KIRK REBECCA: "Genetics: In colorectal cancer, not all KRAS mutations are created equal.", NATURE REVIEWS. CLINICAL ONCOLOGY JAN 2011, vol. 8, no. 1, January 2011 ( ), page 1, XP , ISSN: (B1/EP) FRIDAY ET AL: "K-ras as a target for cancer therapy" BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 2, 25 November 2005 ( ), pages , XP ISSN: X (B1/EP) CARAGLIA MICHELE ET AL: "EGF-R small inhibitors and anti-egf-r antibodies: advantages and limits of a new avenue in anticancer therapy." RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY JUN 2006, vol. 1, no. 2, June 2006 ( ), pages , XP ISSN: (B1/EP) CHUA YU JO ET AL: "Panitumumab" DRUGS OF TODAY, vol. 42, no. 11, November 2006 ( ), pages , XP ISSN: (B1/EP) M C Garassino ET AL: "Effect of tumor-specific KRAS mutational status on impact of anti-egfr therapy in non-small cell lung cancer (NSCLC)", J. Clin. Oncol. 28: 15s (suppl; abstr. 7564), 1 January 2010 ( ), XP , [retrieved on ] (B1/EP) AMADO RAFAEL G ET AL: "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer" JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 26, no. 10, 1 April 2008 ( ), pages , XP ISSN: X (B1/EP) AMADO RAFAEL G ET AL: "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer" JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 26, no. 10, 1 April 2008 ( ), pages , XP ISSN: X (B1) BENVENUTI SILVIA ET AL: "Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies" , 15 March 2007 ( ), XP (B1) CARAGLIA MICHELE ET AL: "EGF-R small inhibitors and anti-egf-r antibodies: advantages and limits of a new avenue in anticancer therapy." RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY JUN 2006, vol. 1, no. 2, June 2006 ( ), pages , XP ISSN: (B1) CHUA YU JO ET AL: "Panitumumab" DRUGS OF TODAY, vol. 42, no. 11, November 2006 ( ), pages , XP ISSN: (B1) EBERHARD D A ET AL: "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib" JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 23, no. 25, 1 September 2004 ( ), pages , XP ISSN: X (B1) WO-A-2007/ (B1) KIRK REBECCA: "Genetics: In colorectal cancer, not all KRAS mutations are created equal.", NATURE REVIEWS. CLINICAL ONCOLOGY JAN 2011, vol. 8, no. 1, January 2011 ( ), page 1, XP , ISSN: (B1) LIÈVRE ASTRID ET AL: "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer." CANCER RESEARCH 15 APR 2006, vol. 66, no. 8, 15 April 2006 ( ), pages , XP ISSN: (B1) M C Garassino ET AL: "Effect of tumor-specific KRAS mutational status on impact of anti-egfr therapy in non-small cell lung cancer (NSCLC)", J. Clin. Oncol. 28: 15s (suppl; abstr. 7564), 1 January 2010 ( ), XP , [retrieved on ] (B1) PAO W ET AL: "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib" PLOS MEDICINE 2005, vol. 2, no. 1, 2005, pages , XP ISSN: (B1) FRIDAY ET AL: "K-ras as a target for cancer therapy" BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 2, 25 November 2005 ( ), pages , XP ISSN: X (B1) Lisens Pant Klage til Klagenemnda Administrativ prøving Innsigelse Protest / Oppreisning Sakshistorikk Statushistorie Hovedstatus Beslutningsdato, detaljstatus

4 Hovedstatus Beslutningsdato, detaljstatus EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt Korrespondanse Dato Type korrespondanse Journal beskrivelse Innkommende EP Publiseringsdokument fra EPO Innkommende EP Publiseringsdokument fra EPO Utgående EP Registreringsbrev Utgående EP Batch Påminnelse om ikke betalt årsavgift (3331) Utgående Betalt gammel stats for årsavgift Utgående Betalt gammel satsa for årsavgift Innkommende, AR Søknadsskjema Patent Innkommende EP Publiseringsdokument fra EPO Informasjon om ikke tilgjengelige dokumenter Betaling Til betaling: Betalingshistorikk: Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status Årsavgift 10. avg. år (EP) ,0 CPA GLOBAL LIMITED Årsavgift 9. avg. år (EP) Computer Patent Årsavgift 8. avg. år (EP) Computer Patent Årsavgift 7. avg. år (EP) Bryn Aarflot AS Onsagers AS Betalt [Kreditering] Årsavgift 7. avg. år (EP) Computer Patent Årsavgift 7. avg. år (EP) Computer Patent Kreditert Betalt Denne oversikten kan mangle informasjon, spesielt for eldre saker, internasjonale varemerker og internasjonale design. Publikasjon(er) Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter) Oversettelse av europeisk patentskrift Norsk Patenttidende (ved meddelelse) Lenker til publikasjoner (ikke søkbare tekstdokumenter) B1/EP

5 Hva betyr A1, B, B1, C osv?